Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations

Nephrology (Carlton). 2006 Oct;11(5):405-9. doi: 10.1111/j.1440-1797.2006.00653.x.

Abstract

Aim: The aim of the present study was to test the feasibility of using commercial preparations of replacement and citrate anticoagulation solution in continuous venovenous haemofiltration (CVVH) in a safe, efficient and simple manner.

Methods: Retrospective review of the database of a large continuous renal replacement therapy programme that uses a standardized prescription of high ultrafiltrate CVVH with commercial solutions for replacement fluid and regional citrate anticoagulation was performed.

Results: Records of 28 patients who underwent 91 CVVH sessions were analysed. Median circuit survival time was 37 (59.5-15.5) h and the 48 h survival probability was 40%. Bleeding or metabolic complications were not noted, and the procedure was simple to administer.

Conclusion: Continuous venovenous haemofiltration using commercial preparations of replacement fluid and citrate anticoagulation can be safe, efficient and simple.

MeSH terms

  • Acute Kidney Injury / mortality
  • Acute Kidney Injury / therapy*
  • Adult
  • Aged
  • Anticoagulants / therapeutic use*
  • Citric Acid / therapeutic use*
  • Female
  • Glucose / therapeutic use
  • Hemofiltration / methods*
  • Humans
  • Isotonic Solutions
  • Male
  • Middle Aged
  • Retrospective Studies
  • Survival Rate

Substances

  • Anticoagulants
  • Isotonic Solutions
  • Citric Acid
  • Glucose